Abstract

Metabolic reprogramming is a hallmark of ovarian cancer, enabling tumor progression, immune evasion and drug resistance. The tumor microenvironment (TME) further shapes metabolic adaptations, enabling cancer cells to withstand hypoxia and nutrient deprivation. While organoid models provide a physiologically relevant platform for studying these processes, they still lack immune and vascular components, limiting their ability to fully recapitulate tumor metabolism and drug responses. In this study, we investigated the key metabolic mechanisms involved in ovarian cancer progression, focusing on glycolysis, lipid metabolism and amino acid metabolism. We integrated metabolomic analyses and drug sensitivity assays to explore metabolic-TME interactions using patient-derived, adult stem cell-derived and iPSC-derived organ tissues. Among these, we found that glycolysis, lipid metabolism and amino acid metabolism play a central role in tumor progression and chemotherapy resistance. We identified methylglyoxal (MGO)-mediated BRCA2 dysfunction as a driver of immune escape, a role for sphingolipid signaling in tumor proliferation and a role for kynurenine metabolism in CD8+ T cell suppression. In addition, PI3K/AKT/mTOR and Wnt/β-catenin pathways promote chemoresistance through metabolic adaptation. By elucidating the link between metabolic reprogramming and immune evasion, this study identifies key metabolic vulnerabilities and potential drug targets in ovarian cancer. Our findings support the development of metabolically targeted therapies and increase the utility of organoid-based precision medicine models.

MeSH

Cells, Pharmaceutical Preparations, Amino Acids, Neoplasms, Organoids, Immune System Diseases, Ovarian Neoplasms, Drug Resistance, Immune Evasion

Cited by

• Revolutionizing cervical cancer treatment: single-cell sequencing of TSPAN1+ tumor EPCs and immune checkpoints to assess drug sensitivity and optimize therapy. Front Immunol, 2025
• The role and mechanism of fatty acid oxidation in cancer drug resistance. Cell Death Discov, 2025
• Single-cell technologies and spatial transcriptomics: decoding immune low - response states in endometrial cancer. Front Immunol, 2025
• Multi-omics dissection of tumor microenvironment-mediated drug resistance: mechanisms and therapeutic reprogramming. Front Pharmacol, 2025
• The potential of ME1 in guiding immunotherapeutic strategies for ovarian cancer: insights from pan-cancer research. Front Immunol, 2025